Protox Therapeutics has received institutional regard board approvals to proceed with its Phase IIa clinical testing evaluating PRX302 representing the treatment of localized recurrent prostate cancer. The compa. Vancouver, BC, January 30, 2008--Protox Therapeutics announced that it has received conditional approval representing the listing of its commonplace shares on the Toronto Stock Exchange.. Vancouver, BC, January 15, 2008--(T-Net)--Protox Therapeutics (TSX-V:PRX), a leader in the event of targeted therapeutic proteins, today announced that the Company has received Institutional Review Board approvals to proceed with . 3 /CNW/ - Protox(TM) Therapeutics Inc. (TSX-V: PRX), aleader in advancing novel, targeted protein
wrinkle toxin therapeutics representing thetreatment of cancer and other proliferative diseases, today announced positivefinal results from its Phase 1 . Vancouver, BC, January 30, 2008--Protox Therapeutics announced that it has received conditional approval representing the listing of its commonplace shares on the Toronto Stock Exchange.. 15 /CNW/ - Protox Therapeutics Inc. (TSX-V:PRX), a leaderin the event of targeted therapeutic proteins, today announced that theCompany has received Institutional Review Board (IRB) approvals to proceedwith its Phase 2a clinical . VANCOUVER - Protox Therapeutics Inc. (TSXV:PRX) has reported a positive Phase 1 memorize on its PRX302 drug candidate representing benign prostatic hyperplasia, a commonplace condition amidst aging males. Protox said Thursday that results from the testing . Vancouver, BC, January 15, 2008--Protox Therapeutics today announced that the Company has received Institutional Review Board approvals to proceed with its Phase 2a clinical testing evaluating PRX302 representing the treatment of localized . 13, 2008 /CNW/ - Protox Therapeutics Inc. (TSX: PRX), a leader in advancing novel, targeted therapeutic proteins, today announced that data from the completed Phase 1 clinical memorize testing PRX302 in patients.
Labels: Initiates, Protox